Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 82 clinical trials
  • 0 views
  • 14 May, 2022
  • 1 location
Evaluating Efficacy and Safety of Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning Failure) to Imatinib or Dasatinib

Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML) and is the current standard of care in the treatment of patients with newly diagnosed CML. However, about 30% of

  • 2 views
  • 11 Jun, 2021
  • 1 location
A Study for Tyrosine Kinase Inhibitors Discontinuation

Treatment of Chronic Myeloid Leukemia (CML) has been revolutionized by the use of tyrosine kinase inhibitors including imatinib mesylate (Gleevec, Novartis Laboratories). Two other inhibitors of

nilotinib
myeloid leukemia
chronic myeloid leukemia
remission
imatinib
  • 0 views
  • 22 Jan, 2021
  • 1 location
Antineoplastic Drugs in Elderly Patients

The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in

primary cancer
paclitaxel
  • 0 views
  • 28 Jul, 2022
  • 1 location
Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy in Ph+ ALL

The use of imatinib in combination with chemotherapy is now considered as the gold standard for the treatment of Ph+ ALL. The complete remission (CR) rate is 90% versus 20% to 40% with

tyrosine
dasatinib
philadelphia chromosome
nilotinib
remission
  • 8 views
  • 22 Jan, 2021
  • 3 locations
French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients Treated With Avapritinib

relies on adequate surgery without tumor spillage and sometimes systemic treatment with imatinib according to risk of relapse defined by localization, tumor size and mitotic count, as well as mutational

  • 0 views
  • 23 Jun, 2021
  • 6 locations
TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study (TIKlet)

Rationale The pharmacokinetics of imatinib and nilotinib, two BCR/Abl tyrosine-kinase inhibitors (TKI), is variable among patients suffering from chronic myeloid leukemia (CML

nilotinib
imatinib
leukemia
tyrosine
bcr-abl protein
  • 0 views
  • 24 Mar, 2022
Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients (GIST)

compared with the other solid tumors. C-KIT or PDGFRA mutation is found in approximately 85-90% of GISTs. Imatinib, a tyrosine kinase inhibitor targeting c-KIT, has been used to treat advanced GIST

  • 0 views
  • 27 Jun, 2022
  • 12 locations
GIST: Assessment of Tumor Mutations and TKI Plasma Exposure

therapies. However, response to TKIs is extremely heterogeneous: ~15% of the patients experience no benefit from imatinib, whereas ~17% of the patients enjoy stable disease for over 9 years. Treatment

  • 1 views
  • 29 May, 2022
  • 1 location
Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors (CML1012)

The objective of this study is to acquire more information about what we are doing during pregnancy in CML patients, in order to possibly establish in the future a consensus on the management of patients receiving TKIs who wants to father a child or become/are pregnant.

tyrosine
  • 13 views
  • 25 Mar, 2022
  • 36 locations